Dr. Shebli Atrash, MD

Dr. Atrash practices at Atrium Health Carolinas Medical Center in Charlotte, North Carolina, part of Advocate Health.

Dr. Atrash's NPI, 1417105941, was assigned on September 9, 2008. Dr. Atrash graduated from Damascus University Faculty of Medicine in 2004. Dr. Atrash's North Carolina license number on file is 2017-01175.

Dr. Atrash's primary practice is Atrium Health Carolinas Medical Center, at 1000 Blythe Blvd, Charlotte, NC 28203 in Mecklenburg County. The practice phone is (704) 355-2000.

Dr. Atrash's primary practice is Atrium Health Carolinas Medical Center in Charlotte, North Carolina, part of Advocate Health. Dr. Atrash is also affiliated with Atrium Health Cabarrus. The medical group on file is Atrium Health Levine Cancer Institute. Dmand AI also links Dr. Atrash to 1 more group practice or clinic, named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Atrash practices, 3 sites in all. Vendor and product names are available with a free account.

Hematology and oncology is Dr. Atrash's primary specialty in the NPI Registry, under taxonomy code 207RH0003X. Dr. Atrash is board certified in hematology by the American Board of Internal Medicine. Dmand AI has Dr. Atrash's licenses on file in 3 states: North Carolina, South Carolina and Arkansas.

Dmand AI lists chronic anemia, colorectal cancer, lymphoma and multiple myeloma among the conditions Dr. Atrash treats.

CMS data shows 359 Medicare services from Dr. Atrash across 2 procedure codes in 2024, all of them office visits, for 169 Medicare patients. Medicare paid $21,675 for them.

CMS counts 169 Medicare patients who saw Dr. Atrash in 2024. The largest group is 65 to 74, with 85 patients. 70% of them have high blood pressure, and 61% have high cholesterol. Their average risk score is 2.66, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Atrash's median patient age at 72, with 40% women.

In 2024, Dr. Atrash wrote 563 Medicare Part D claims for 104 patients. 85% of them were for generic drugs. CMS names the drug for 376 of them, across 12 drugs with 11 or more claims each, at $23,613 in total drug cost. In 2023, CMS named 497 claims across 14 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 100 out of 100 for Dr. Atrash for performance year 2024, reported as part of a group. Dr. Atrash accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Atrash as offering telehealth.

Dmand AI links 62 papers to Dr. Atrash, published from 2012 to 2025. 2020 was the busiest year, with 8. The most frequent topics are Multiple Myeloma, Antibodies, Monoclonal and Antineoplastic Combined Chemotherapy Protocols. Dr. Atrash has published most often in Clin Lymphoma Myeloma Leuk. Dr. Atrash's most frequent co-authors are Saad Z. Usmani, MD, Manisha Bhutani, MD and Nausheen Ahmed, MD.

Dmand AI links Dr. Atrash to 9 clinical trials, 3 of them phase 2 studies. 5 are still active or recruiting. Conditions studied include Multiple Myeloma, Blood Protein Disorders and Neoplasms, Plasma Cell. University of Arkansas sponsors the most, 6. Open Payments lists research payments to Dr. Atrash that name 1 trial.

CMS Open Payments shows 240 general payments to Dr. Atrash from 20 drug and device companies from 2017 to 2025. Consulting fees make up the largest share, 94% of the total. Pfizer Inc. paid the most, $857,663. It also lists 10 research payments totaling $5,716 from 2019 to 2022, naming 1 clinical trial.

Dr. Atrash serves on International Myeloma Working Group, ACCRU and SWOG.

Dr. Atrash graduated from Damascus University Faculty of Medicine in 2004. Dr. Atrash is a member of ACP, ASCO, ASH and European Hematology Association.

Dr. Atrash is in network with 22 carriers, including Aetna, Elevance and Blue Cross Blue Shield of Michigan. PPO plans come from the most carriers, 12. Check the plan with the practice before a visit.